/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.
BOSTON and ATLANTA, Aug. 7, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of.
BOSTON and ATLANTA, July 17, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of.
BOSTON and ATLANTA, June 29, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of